Please login to the form below

ivabradine

This page shows the latest ivabradine news and features for those working in and with pharma, biotech and healthcare.

than Novartis’ Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine), which were both approved for heart failure in 2015.

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.
Amgen agrees to take Cytokinetics' heart failure drug into phase III

It sits among a new generation of heart failure therapies - spearheaded by Novartis' Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine) - which are trying to advance the treatment of heart
Shire and Baxalta drugs among CHMP's latest recommendations

ANPHARM Przedsiębiorstwo Farmaceutyczne's Ivabradine Anpharm (ivabradine) for the treatment of stable chronic angina pectoris and chronic heart failure.
Amgen starts shipping Corlaner in US

Corlaner (ivabradine) - the first new medicine for chronic heart failure in the US in almost a decade - will be available in pharmacies before the end of the week, according to
FDA clears Amgen's Corlaner for heart failure

The FDA approved Corlaner (ivabradine) after a priority review for reducing the risk of hospitalisation for worsening heart failure in patients with stable, symptomatic chronic heart failure (CHF). . ... on ivabradine sales on the back of US approval

More from news
Approximately 5 fully matching, plus 7 partially matching documents found.

Heart failure therapy embarks on a new era

While Entresto has captured the headlines of late, there was another key development in HF therapy this year after Amgen secured approval in the US for Corlaner (ivabradine), a drug that ... Ivabradine is thought to be the first drug to work by
Deal Watch table for July 2013

100. ‡‡Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2). ... Over 40 European countries, Australia, New Zealand . ‡ North America. ‡‡ Amgen
Pharma deals during July 2013

Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!: EXCELLENT DAY RATES AVAILABLE

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Add my company

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...